{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:16Z","timestamp":1792784896058,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"FERRING Pharmaceuticals Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The impact of gonadotropin-releasing hormone (GnRH) antagonist and agonist (GnRHa) treatment on cardiovascular disease (CVD) risk in prostate cancer (PCa) remains inconclusive due to conflicting findings. We compared the effects of GnRH antagonist and GnRHa treatments on CVD risk in patients with PCa and pre-existing CVD, in a Taiwan population-based database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We assessed the risk of major adverse CV events (MACE: ischemic heart disease [IHD], stroke, congestive heart failure [CHF] or all cause deaths) and composite CV events (IHD, stroke, CHF or CV deaths) occurring \u226590 days after androgen deprivation therapy (ADT) initiation in patients with PCa after 90 days of treatment with either GnRH antagonist (degarelix;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009499) or GnRHa (goserelin, leuprolide, triptorelin;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915,127). Patients identified with pre-existing CVD had received cardiac therapy for IHD, reported a stroke or CHF within a year before ADT initiation. Adjusted hazard ratios (aHR) and 95% confidence interval (CI) were obtained for MACE and composite CV events risk after adjusting for age, baseline status of diabetes, hypertension and treatments received.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All GnRH antagonist-treated patients showed lower risk of composite CV events than the GnRHa-treated patients. The lower composite CV events risk associated with GnRH antagonist was also observed in patients with metastasis at diagnosis (aHR 0.16; 95% CI, 0.04\u20130.38;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013) and those receiving ADT for more than six months (aHR 0.30; 95% CI, 0.16\u20130.54;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). In patients with pre-existing CVD, the MACE risk was 33% lower (aHR 0.67; 95% CI, 0.46\u20130.96;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0299) and composite CV events risk was 84% lower (aHR 0.16; 95% CI, 0.05\u20130.50;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0017) in GnRH antagonist-treated than the GnRHa-treated patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with PCa and pre-existing CVD, GnRH antagonist use was associated with lower risks for composite CV events and MACE compared with GnRHa.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-022-00555-0","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T05:05:13Z","timestamp":1654232713000},"page":"722-729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-1901","authenticated-orcid":false,"given":"Yu-Hsuan Joni","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hua","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"555_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"555_CR2","doi-asserted-by":"publisher","first-page":"1408793","DOI":"10.1155\/2020\/1408793","volume":"2020","author":"YC Huang","year":"2020","unstructured":"Huang YC, Chen YH. Cancer incidence characteristic evolution based on the National Cancer Registry in Taiwan. J Oncol. 2020;2020:1408793.","journal-title":"J Oncol"},{"key":"555_CR3","unstructured":"Ministry of Health and Welfare ROCT. Taiwan health and welfare report 2017. Ministry of Health and Welfare, R.O.C. (Taiwan): Taipei City, Taiwan, 2018."},{"key":"555_CR4","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","volume":"40","author":"KM Sturgeon","year":"2019","unstructured":"Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40:3889\u201397.","journal-title":"Eur Heart J"},{"key":"555_CR5","doi-asserted-by":"publisher","first-page":"e2119568","DOI":"10.1001\/jamanetworkopen.2021.19568","volume":"4","author":"AO Elmehrath","year":"2021","unstructured":"Elmehrath AO, Afifi AM, Al-Husseini MJ, Saad AM, Wilson N, Shohdy KS, et al. Causes of death among patients with metastatic prostate cancer in the US from 2000 to 2016. JAMA Netw Open. 2021;4:e2119568.","journal-title":"JAMA Netw Open"},{"key":"555_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/bju.12212","volume":"112","author":"S Chowdhury","year":"2013","unstructured":"Chowdhury S, Robinson D, Cahill D, Rodriguez-Vida A, Holmberg L, Moller H. Causes of death in men with prostate cancer: an analysis of 50,000 men from the Thames Cancer Registry. BJU Int. 2013;112:182\u20139.","journal-title":"BJU Int"},{"key":"555_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15639-5","volume":"11","author":"KC Stoltzfus","year":"2020","unstructured":"Stoltzfus KC, Zhang Y, Sturgeon K, Sinoway LI, Trifiletti DM, Chinchilli VM, et al. Fatal heart disease among cancer patients. Nat Commun. 2020;11:2011.","journal-title":"Nat Commun"},{"key":"555_CR8","doi-asserted-by":"publisher","first-page":"188383","DOI":"10.1016\/j.bbcan.2020.188383","volume":"1874","author":"S Muniyan","year":"2020","unstructured":"Muniyan S, Xi L, Datta K, Das A, Teply BA, Batra SK, et al. Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients. Biochim Biophys Acta Rev Cancer. 2020;1874:188383.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"555_CR9","doi-asserted-by":"publisher","first-page":"e000082","DOI":"10.1161\/HCG.0000000000000082","volume":"14","author":"TM Okwuosa","year":"2021","unstructured":"Okwuosa TM, Morgans A, Rhee JW, Reding KW, Maliski S, Plana JC, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2021;14:e000082.","journal-title":"Circ Genom Precis Med"},{"key":"555_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/aja.aja_22_20","volume":"23","author":"SJ Freedland","year":"2021","unstructured":"Freedland SJ, Abrahamsson PA. Androgen deprivation therapy and side effects: are GnRH antagonists safer? Asian J Androl. 2021;23:3\u201310.","journal-title":"Asian J Androl"},{"key":"555_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2017.03.002","volume":"77","author":"LM Scailteux","year":"2017","unstructured":"Scailteux LM, Vincendeau S, Balusson F, Leclercq C, Happe A, Le Nautout B, et al. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data. Eur J Cancer. 2017;77:99\u2013108.","journal-title":"Eur J Cancer"},{"key":"555_CR12","first-page":"E307","volume":"15","author":"A Kokorovic","year":"2021","unstructured":"Kokorovic A, So AI, Serag H, French C, Hamilton RJ, Izard JP, et al. Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies. Can Urol Assoc J 2021;15:E307\u2013E322.","journal-title":"Can Urol Assoc J"},{"key":"555_CR13","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/pros.24187","volume":"81","author":"DY Chen","year":"2021","unstructured":"Chen DY, Su PJ, See LC, Liu JR, Chuang CK, Pang ST, et al. Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: a nationwide cohort and in vitro study. Prostate 2021;81:902\u201312.","journal-title":"Prostate"},{"key":"555_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","volume":"65","author":"PC Albertsen","year":"2014","unstructured":"Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65:565\u201373.","journal-title":"Eur Urol"},{"key":"555_CR15","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/JU.0000000000000714","volume":"203","author":"DP Leong","year":"2020","unstructured":"Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, et al. Cardiovascular risk in men with prostate cancer: Insights from the RADICAL PC Study. J Urol. 2020;203:1109\u201316.","journal-title":"J Urol"},{"key":"555_CR16","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1097\/JU.0000000000000384","volume":"202","author":"D Margel","year":"2019","unstructured":"Margel D, Peer A, Ber Y, Shavit-Grievink L, Tabachnik T, Sela S, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. J Urol. 2019;202:1199\u2013208.","journal-title":"J Urol"},{"key":"555_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.eururo.2020.06.002","volume":"79","author":"M Abufaraj","year":"2021","unstructured":"Abufaraj M, Iwata T, Kimura S, Haddad A, Al-Ani H, Abusubaih L, et al. Differential impact of gonadotropin-releasing hormone antagonist versus agonist on clinical safety and oncologic outcomes on patients with metastatic prostate cancer: a meta-analysis of randomized controlled trials. Eur Urol. 2021;79:44\u201353.","journal-title":"Eur Urol"},{"key":"555_CR18","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","volume":"144","author":"RD Lopes","year":"1999","unstructured":"Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sorensen PS, et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. 2021;144:1295\u20131307.","journal-title":"Circulation"},{"key":"555_CR19","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","volume":"102","author":"L Klotz","year":"2008","unstructured":"Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531\u20138.","journal-title":"BJU Int"},{"key":"555_CR20","doi-asserted-by":"publisher","first-page":"e3845","DOI":"10.1097\/MD.0000000000003845","volume":"95","author":"A Sciarra","year":"2016","unstructured":"Sciarra A, Fasulo A, Ciardi A, Petrangeli E, Gentilucci A, Maggi M, et al. A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. Med (Baltim). 2016;95:e3845.","journal-title":"Med (Baltim)"},{"key":"555_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/jjco\/hyu211","volume":"45","author":"CJ Chiang","year":"2015","unstructured":"Chiang CJ, You SL, Chen CJ, Yang YW, Lo WC, Lai MS. Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. Jpn J Clin Oncol. 2015;45:291\u20136.","journal-title":"Jpn J Clin Oncol"},{"key":"555_CR22","doi-asserted-by":"publisher","first-page":"258","DOI":"10.7326\/0003-4819-148-4-200802190-00004","volume":"148","author":"CP Wen","year":"2008","unstructured":"Wen CP, Tsai SP, Chung WS. A 10-year experience with universal health insurance in Taiwan: measuring changes in health and health disparity. Ann Intern Med. 2008;148:258\u201367.","journal-title":"Ann Intern Med"},{"key":"555_CR23","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/ije\/29.2.336","volume":"29","author":"TH Lu","year":"2000","unstructured":"Lu TH, Lee MC, Chou MC. Accuracy of cause-of-death coding in Taiwan: types of miscoding and effects on mortality statistics. Int J Epidemiol. 2000;29:336\u201343.","journal-title":"Int J Epidemiol"},{"key":"555_CR24","unstructured":"American Joint Committee on Cancer. Manual for Staging of Cancer, 5 edn. JB Lippincott: Philadelphia, 1997."},{"key":"555_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pros.23142","volume":"76","author":"ON Kryvenko","year":"2016","unstructured":"Kryvenko ON, Epstein JI. Changes in prostate cancer grading: Including a new patient-centric grading system. Prostate 2016;76:427\u201333.","journal-title":"Prostate"},{"key":"555_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-519","volume":"11","author":"CG Jespersen","year":"2011","unstructured":"Jespersen CG, Norgaard M, Bjerklund Johansen TE, Sogaard M, Borre M. The influence of cardiovascular morbidity on the prognosis in prostate cancer. Experience from a 12-year nationwide Danish population-based cohort study. BMC Cancer. 2011;11:519.","journal-title":"BMC Cancer"},{"key":"555_CR27","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.6004\/jnccn.2012.0114","volume":"10","author":"JL Mohler","year":"2012","unstructured":"Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D\u2019Amico AV, et al. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10:1081\u20137.","journal-title":"J Natl Compr Canc Netw"},{"key":"555_CR28","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/sim.7501","volume":"36","author":"PC Austin","year":"2017","unstructured":"Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36:4391\u20134400.","journal-title":"Stat Med"},{"key":"555_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"555_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/jcph.1332","volume":"59","author":"HH Kao","year":"2019","unstructured":"Kao HH, Kao LT, Li IH, Pan KT, Shih JH, Chou YC, et al. Androgen deprivation therapy use increases the risk of heart failure in patients with prostate cancer: A population-based cohort study. J Clin Pharm. 2019;59:335\u201343.","journal-title":"J Clin Pharm"},{"key":"555_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/andr.12141","volume":"4","author":"LH Wang","year":"2016","unstructured":"Wang LH, Liu CK, Chen CH, Kao LT, Lin HC, Huang CY. No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese\/Taiwanese men. Andrology. 2016;4:128\u201332.","journal-title":"Andrology"},{"key":"555_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/cancers12010189","volume":"12","author":"SY Wu","year":"2020","unstructured":"Wu SY, Fang SC, Hwang OR, Shih HJ, Shao YJ. Influence of baseline cardiovascular comorbidities on mortality after androgen deprivation therapy for metastatic prostate cancer. Cancers (Basel). 2020;12:189.","journal-title":"Cancers (Basel)"},{"key":"555_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00345-020-03433-3","volume":"39","author":"P Davey","year":"2021","unstructured":"Davey P, Kirby MG. Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice. World J Urol. 2021;39:307\u201315.","journal-title":"World J Urol"},{"key":"555_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/TCRM.S249208","volume":"16","author":"V Perrone","year":"2020","unstructured":"Perrone V, Degli Esposti L, Giacomini E, Veronesi C, Blini V, Oderda M. Cardiovascular risk profile in prostate cancer patients treated with GnRH agonists versus antagonists: an Italian real-world analysis. Ther Clin Risk Manag. 2020;16:393\u2013401.","journal-title":"Ther Clin Risk Manag"},{"key":"555_CR35","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","volume":"382","author":"ND Shore","year":"2020","unstructured":"Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N. Engl J Med. 2020;382:2187\u201396.","journal-title":"N. Engl J Med"},{"key":"555_CR36","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/EDE.0000000000001132","volume":"31","author":"CR Cardwell","year":"2020","unstructured":"Cardwell CR, O\u2019Sullivan JM, Jain S, Harbinson MT, Cook MB, Hicks BM, et al. The risk of cardiovascular disease in prostate cancer patients receiving androgen deprivation therapies. Epidemiology 2020;31:432\u201340.","journal-title":"Epidemiology"},{"key":"555_CR37","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1002\/ijc.33397","volume":"148","author":"G George","year":"2021","unstructured":"George G, Garmo H, Scailteux LM, Balusson F, De Coster G, De Schutter H, et al. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases. Int J Cancer. 2021;148:2203\u201311.","journal-title":"Int J Cancer"},{"key":"555_CR38","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35:893\u2013911.","journal-title":"J Clin Oncol"},{"key":"555_CR39","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 2020;22:1945\u201360.","journal-title":"Eur J Heart Fail"},{"key":"555_CR40","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: \u2002The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768\u2013801.","journal-title":"Eur Heart J"},{"key":"555_CR41","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/fcp.12454","volume":"33","author":"G George","year":"2019","unstructured":"George G, Scailteux LM, Garmo H, Balusson F, Cardwell C, Coster G, et al. Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases. Fundam Clin Pharm. 2019;33:479\u201399.","journal-title":"Fundam Clin Pharm"},{"key":"555_CR42","doi-asserted-by":"publisher","first-page":"e210070","DOI":"10.1001\/jamanetworkopen.2021.0070","volume":"4","author":"L Sun","year":"2021","unstructured":"Sun L, Parikh RB, Hubbard RA, Cashy J, Takvorian SU, Vaughn DJ, et al. Assessment and management of cardiovascular risk factors among US veterans with prostate cancer. JAMA Netw Open. 2021;4:e210070.","journal-title":"JAMA Netw Open"},{"key":"555_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75139-w","volume":"10","author":"CF Ng","year":"2020","unstructured":"Ng CF, Chiu PKF, Yee CH, Lau BSY, Leung SCH, Teoh JYC. Effect of androgen deprivation therapy on cardiovascular function in Chinese patients with advanced prostate cancer: a prospective cohort study. Sci Rep. 2020;10:18060.","journal-title":"Sci Rep"},{"key":"555_CR44","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00345-016-1818-2","volume":"34","author":"DJ Rosario","year":"2016","unstructured":"Rosario DJ, Davey P, Green J, Greene D, Turner B, Payne H, et al. The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK. World J Urol. 2016;34:1601\u20139.","journal-title":"World J Urol"},{"key":"555_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11864-021-00846-z","volume":"22","author":"AA Challa","year":"2021","unstructured":"Challa AA, Calaway AC, Cullen J, Garcia J, Desai N, Weintraub NL, et al. Cardiovascular toxicities of androgen deprivation therapy. Curr Treat Options Oncol. 2021;22:47.","journal-title":"Curr Treat Options Oncol"},{"key":"555_CR46","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/iju.14303","volume":"27","author":"H Van Poppel","year":"2020","unstructured":"Van Poppel H, Abrahamsson PA. Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer. Int J Urol. 2020;27:830\u20137.","journal-title":"Int J Urol"},{"key":"555_CR47","first-page":"743","volume":"84","author":"HF Chen","year":"1999","unstructured":"Chen HF, Jeung EB, Stephenson M, Leung PC. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab. 1999;84:743\u201350.","journal-title":"J Clin Endocrinol Metab"},{"key":"555_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2249.2005.02904.x","volume":"142","author":"F Tanriverdi","year":"2005","unstructured":"Tanriverdi F, Gonzalez-Martinez D, Hu Y, Kelestimur F, Bouloux PM. GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol. 2005;142:103\u201310.","journal-title":"Clin Exp Immunol"},{"key":"555_CR49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1161\/ATVBAHA.119.312802","volume":"40","author":"TJ Barrett","year":"2020","unstructured":"Barrett TJ. Macrophages in atherosclerosis regression. Arterioscler Thromb Vasc Biol. 2020;40:20\u201333.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"555_CR50","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1097\/JU.0000000000001879","volume":"206","author":"K Lifshitz","year":"2021","unstructured":"Lifshitz K, Ber Y, Shenhar C, Nillson J, Peer A, Rosenbaum E, et al. Cardiovascular proteomics: A post hoc analysis from a phase II randomized clinical trial comparing GnRH antagonist vs GnRH agonist among men with advanced prostate cancer. J Urol. 2021;206:952\u20139.","journal-title":"J Urol"},{"key":"555_CR51","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 Study. J Am Coll Cardiol 2020;76:2982\u20133021.","journal-title":"J Am Coll Cardiol"}],"updated-by":[{"DOI":"10.1038\/s41391-022-00568-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000}},{"DOI":"10.1038\/s41391-022-00596-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000}}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00555-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00555-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00555-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T03:02:09Z","timestamp":1699585329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00555-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1038\/s41391-022-00555-0","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"28 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41391-022-00596-5","URL":"https:\/\/doi.org\/10.1038\/s41391-022-00596-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41391-022-00568-9","URL":"https:\/\/doi.org\/10.1038\/s41391-022-00568-9","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted according to the Declaration of Helsinki and the International Society for Pharmacoepidemiology Guidelines for Good Pharmacoepidemiology Practices. It was carried out retrospectively using an anonymized database. This study was reviewed and approved by the Institutional Review Board of Taipei Medical University (TMU-JIRB no. 201502042). All authors had full access to the data and take responsibility for data integrity and analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}